PE30891A1 - Composiciones y metodos terapeuticos sinergicos - Google Patents
Composiciones y metodos terapeuticos sinergicosInfo
- Publication number
- PE30891A1 PE30891A1 PE1991185538A PE18553891A PE30891A1 PE 30891 A1 PE30891 A1 PE 30891A1 PE 1991185538 A PE1991185538 A PE 1991185538A PE 18553891 A PE18553891 A PE 18553891A PE 30891 A1 PE30891 A1 PE 30891A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- therapeutic compositions
- synergic
- synergic therapeutic
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
EL METODO CONSISTE EN ADMINISTRAR A UN MAMIFERO CANTIDADES DE POR LO MENOS DOS AGENTES TERAPEUTICOS SELECCIONADOS ENTRE EL GRUPO FORMADO POR: (a) A UN INHIBIDOR DE LA RENINA;(b) UN INHIBIDOR DE LAS ENZIMAS CONVERTIDORAS DE ANGIOTENSINA I Y (c) UN ANTAGONISTA DE LA ANGIOTENSINA II, DONDE LA CANTIDAD DE (a), (b Y (c) POR SI SOLOS ES INSUFICIENTE PARA CONSEGUIR EL EFECTO TERAPEUTICO, SIENDO EL EFECTO COMBINADO DE LAS CANTIDADES DE LOS AGENTES TERAPEUTICOS ADMINISTRADOS SUPERIOR A LA SUMA DE LOS AGENTES TERAPEUTICOS INDIVIDUALES ADMINISTRADOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52236090A | 1990-05-11 | 1990-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE30891A1 true PE30891A1 (es) | 1991-11-27 |
Family
ID=24080550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1991185538A PE30891A1 (es) | 1990-05-11 | 1991-05-10 | Composiciones y metodos terapeuticos sinergicos |
Country Status (34)
Country | Link |
---|---|
US (2) | US6900234B1 (es) |
EP (1) | EP0527879B1 (es) |
JP (2) | JPH0729938B2 (es) |
KR (1) | KR970005839B1 (es) |
CN (7) | CN101156949A (es) |
AP (1) | AP240A (es) |
AT (1) | ATE148632T1 (es) |
AU (1) | AU653724B2 (es) |
BG (1) | BG61831B1 (es) |
BR (1) | BR9106438A (es) |
CA (1) | CA2081564C (es) |
DE (1) | DE69124598T2 (es) |
DK (1) | DK0527879T3 (es) |
EG (1) | EG19648A (es) |
ES (1) | ES2097208T3 (es) |
GR (1) | GR3022997T3 (es) |
GT (1) | GT199100032A (es) |
HK (1) | HK1094148A1 (es) |
HU (1) | HU227346B1 (es) |
IE (1) | IE911592A1 (es) |
IL (1) | IL98055A (es) |
IS (1) | IS2042B (es) |
MA (1) | MA22150A1 (es) |
MY (1) | MY114347A (es) |
NO (1) | NO924321L (es) |
NZ (1) | NZ238118A (es) |
PE (1) | PE30891A1 (es) |
PT (1) | PT97615B (es) |
RO (1) | RO115786B1 (es) |
RU (1) | RU2147875C1 (es) |
TW (1) | TW203553B (es) |
WO (1) | WO1991017771A1 (es) |
YU (1) | YU49094B (es) |
ZA (1) | ZA913539B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2097208T3 (es) * | 1990-05-11 | 1997-04-01 | Pfizer | Composiciones y procedimientos terapeuticos y sinergicos. |
EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
DE4340437C1 (de) * | 1993-11-27 | 1995-05-24 | Karla Dr Lehmann | Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen |
EP0820302A1 (en) * | 1995-04-07 | 1998-01-28 | Novartis AG | Combination compositions containing benazepril or benazeprilat and valsartan |
EP0835106A4 (en) * | 1995-06-30 | 1998-09-30 | Merck & Co Inc | METHOD FOR TREATING KIDNEY DISEASES USING AN ACE INHIBITOR AND AII ANTAGONIST |
WO1997037688A2 (en) * | 1996-04-05 | 1997-10-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity |
CA2257946A1 (en) * | 1996-06-24 | 1997-12-31 | Merck & Co., Inc. | A composition of enalapril and losartan |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
WO1999015643A2 (en) * | 1997-09-25 | 1999-04-01 | University Of Florida | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE |
HUP0100427A3 (en) * | 1997-12-23 | 2002-11-28 | Warner Lambert Co | Ace inhibitor-mmp inhibitor combinations |
US6087343A (en) * | 1998-09-14 | 2000-07-11 | University Of Florida | Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use |
US6387894B1 (en) * | 1999-06-11 | 2002-05-14 | Pfizer Inc. | Use of CRF antagonists and renin-angiotensin system inhibitors |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
AU2003250858A1 (en) * | 2002-06-28 | 2004-01-19 | Novartis Ag | Use of organic compounds |
SI1615646T2 (sl) | 2003-04-08 | 2022-11-30 | Progenics Pharmaceuticals, Inc. | Farmacevtske formulacije vsebujoče metilnatrekson |
US20040265238A1 (en) | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
JP2008515903A (ja) * | 2004-10-08 | 2008-05-15 | ノバルティス アクチエンゲゼルシャフト | 拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用 |
CN104248763A (zh) * | 2005-03-07 | 2014-12-31 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
AR065877A1 (es) | 2007-03-29 | 2009-07-08 | Progenics Pharm Inc | Antagonoistas del receptor opioide periferico y usos de los mismos |
MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
CN102423483A (zh) * | 2011-11-24 | 2012-04-25 | 西北农林科技大学 | 一种复方雷米普利纳米乳抗高血压药物 |
CN114032273B (zh) * | 2021-11-17 | 2024-02-02 | 山东省科学院生物研究所 | 一种多功能西洋参水解肽及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US324377A (en) * | 1885-08-18 | Roller-skate | ||
US4046889A (en) * | 1976-02-13 | 1977-09-06 | E. R. Squibb & Sons, Inc. | Azetidine-2-carboxylic acid derivatives |
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
US4749688A (en) | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US4814342A (en) | 1986-10-31 | 1989-03-21 | Pfizer Inc. | Nor-statine and nor-cyclostatine polypeptides |
US4895834A (en) * | 1986-12-15 | 1990-01-23 | Warner-Lambert Company | Renin inhibitors III |
US4962105A (en) | 1987-10-19 | 1990-10-09 | Ciba-Geigy Corporation | Potentiation of antihypertensive effect of ace inhibitors |
US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
IL91780A (en) | 1988-10-04 | 1995-08-31 | Abbott Lab | History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them |
ES2097208T3 (es) * | 1990-05-11 | 1997-04-01 | Pfizer | Composiciones y procedimientos terapeuticos y sinergicos. |
-
1991
- 1991-04-22 ES ES91909382T patent/ES2097208T3/es not_active Expired - Lifetime
- 1991-04-22 BR BR919106438A patent/BR9106438A/pt not_active Application Discontinuation
- 1991-04-22 EP EP91909382A patent/EP0527879B1/en not_active Expired - Lifetime
- 1991-04-22 AU AU78591/91A patent/AU653724B2/en not_active Expired
- 1991-04-22 AT AT91909382T patent/ATE148632T1/de not_active IP Right Cessation
- 1991-04-22 CA CA002081564A patent/CA2081564C/en not_active Expired - Lifetime
- 1991-04-22 DK DK91909382.3T patent/DK0527879T3/da active
- 1991-04-22 RU RU92016534A patent/RU2147875C1/ru active
- 1991-04-22 WO PCT/US1991/002733 patent/WO1991017771A1/en active IP Right Grant
- 1991-04-22 DE DE69124598T patent/DE69124598T2/de not_active Expired - Lifetime
- 1991-04-22 HU HU9203522A patent/HU227346B1/hu unknown
- 1991-04-22 KR KR1019920702805A patent/KR970005839B1/ko not_active IP Right Cessation
- 1991-04-22 JP JP3508991A patent/JPH0729938B2/ja not_active Expired - Lifetime
- 1991-04-22 RO RO92-01405A patent/RO115786B1/ro unknown
- 1991-05-01 TW TW080103439A patent/TW203553B/zh not_active IP Right Cessation
- 1991-05-03 IL IL9805591A patent/IL98055A/en not_active IP Right Cessation
- 1991-05-06 AP APAP/P/1991/000258A patent/AP240A/en active
- 1991-05-08 EG EG27891A patent/EG19648A/xx active
- 1991-05-08 MA MA22420A patent/MA22150A1/fr unknown
- 1991-05-09 PT PT97615A patent/PT97615B/pt not_active IP Right Cessation
- 1991-05-10 CN CNA2007101867127A patent/CN101156949A/zh active Pending
- 1991-05-10 PE PE1991185538A patent/PE30891A1/es unknown
- 1991-05-10 CN CNA2006101018493A patent/CN1915428A/zh active Pending
- 1991-05-10 GT GT199100032A patent/GT199100032A/es unknown
- 1991-05-10 CN CN91103177A patent/CN1065140C/zh not_active Expired - Lifetime
- 1991-05-10 CN CNB2003101199156A patent/CN100358578C/zh not_active Expired - Lifetime
- 1991-05-10 YU YU81991A patent/YU49094B/sh unknown
- 1991-05-10 IE IE159291A patent/IE911592A1/en not_active IP Right Cessation
- 1991-05-10 CN CN2005100035730A patent/CN1824315B/zh not_active Expired - Lifetime
- 1991-05-10 ZA ZA913539A patent/ZA913539B/xx unknown
- 1991-05-10 IS IS3703A patent/IS2042B/is unknown
- 1991-05-10 MY MYPI91000798A patent/MY114347A/en unknown
- 1991-05-10 CN CNA2006100934632A patent/CN1879884A/zh active Pending
- 1991-05-10 NZ NZ238118A patent/NZ238118A/en unknown
-
1992
- 1992-11-10 NO NO92924321A patent/NO924321L/no unknown
- 1992-11-10 BG BG97068A patent/BG61831B1/bg unknown
-
1994
- 1994-06-27 JP JP6144998A patent/JP2635291B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/463,878 patent/US6900234B1/en not_active Expired - Lifetime
- 1995-06-05 US US08/465,660 patent/US6716875B1/en not_active Expired - Lifetime
-
1997
- 1997-04-01 GR GR970400671T patent/GR3022997T3/el unknown
-
2000
- 2000-04-29 CN CN00108186A patent/CN1307901A/zh active Pending
-
2006
- 2006-12-21 HK HK06114077.1A patent/HK1094148A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE30891A1 (es) | Composiciones y metodos terapeuticos sinergicos | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
ATE91233T1 (de) | Antivirale pharmazeutische zusammensetzungen und ihrer verwendung. | |
CO4410317A1 (es) | Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos. | |
ES2190472T3 (es) | Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno. | |
ES2189235T3 (es) | 6-fenilfenantridinas sustituidas. | |
ECSP024364A (es) | Antagonistas receptores de adenosina a2a | |
CO5011115A1 (es) | Compuestos y metodos quimioquina | |
ES2094721T3 (es) | Analogos de la camptotecina solubles en agua. | |
FI952680A0 (fi) | Injektoitavia taksaanijohdannaisiin pohjautuvia koostumuksia | |
ECSP941135A (es) | Antagonistas triciclicos de vasopresina de benzacepina | |
ES2060635T3 (es) | Fenilglicinas para usar en la reduccion de la lesion neurotoxica. | |
ES2164303T3 (es) | Composicion acuosa de curado acelerado exenta de formaldehido para unir materiales no tejidos de fibra de vidrio resistentes al calor. | |
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
EA199800357A1 (ru) | Фармацевтические ангиостатические дипептидные композиции и способы их применения | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
FI963462A0 (fi) | Bentsotiofeeni-, bentsofuraani- ja indolitiatsepinonit, -oksatsepinonit ja -diatsepinonit soluadheesion estäjinä ja HIV:n estäjinä | |
EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
KR950702120A (ko) | 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis) | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
ES2194933T3 (es) | Inhibidores de la agregacion plaquetaria. | |
FI934680A0 (fi) | Arylmorfolin, framstaellning och anvaending | |
ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
ES2140672T3 (es) | Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos. |